Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Children's Oncology Group
- Study ID
- NCT00138216
- Phase
- PHASE1
- Status
- Completed
Conditions
- Brain and Central Nervous System Tumors
- Unspecified Childhood Solid Tumor, Protocol Specific
Eligibility Criteria
- Sex
- ALL
- Age
- 1 Year - 21 Years
- Healthy Volunteers
- Not accepted
Interventions
- irinotecan hydrochloride — DRUG
- temozolomide — DRUG
- vincristine sulfate — DRUG
Study Details
RATIONALE: Drugs used in chemotherapy, such as temozolomide, vincristine, and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of irinotecan when given together with temozolomide and vincristine in treating young patients with refractory solid tumors.
Key Dates
- Start date
- Oct 31, 2005
- Status verified
- Feb 2014
- Primary completion
- Jun 30, 2009
- Completion
- Jan 31, 2011
Study Design
- Enrollment
- 42 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Oral Irinotecan, temozolomide and vincristine sulfatesee detailed description
Primary Outcome Measure
Determine maximum tolerated dose (MTD) of oral irinotecan [ Time Frame: length of study ]
Locations (16)
Find similar trials in Birmingham, AL
By research site
Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham· Birmingham, ALChildren's Hospital of Orange County· Orange, CAStanford Cancer Center· Stanford, CAChildren's Memorial Hospital - Chicago· Chicago, ILIndiana University Melvin and Bren Simon Cancer Center· Indianapolis, INDana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute· Boston, MA
Related Studies
- Collection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid TumorsRecruiting · Wake Forest University Health Sciences · Winston-Salem, North Carolina
- 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With CancerRecruiting · Barbara Ann Karmanos Cancer Institute · Detroit, Michigan
- Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent GlioblastomaPHASE1/PHASE2 · Recruiting · National Institute of Neurological Disorders and Stroke (NINDS) · Bethesda, Maryland